The global digital telepathology market size is likely to reach a valuation of US$ 776.8 million in 2023. The expanding value in the healthcare sector and a wide range of applications are projected to be the market's primary growth drivers.
The overall sales of digital telepathology equipment are projected to expand at a notable CAGR of 9.7% between 2023 and 2033, totaling around US$ 1962.2 million by the end of 2033.
Pathology is the study of diseases and is one of the most pertinent branches of medicine and diagnosis. It is primarily concerned with the causes, origins, and investigation of various conditions. Further, it is accomplished by examining bodily fluids, tissues, and organs. It is currently divided into eight significant study areas.
The digital telepathology industry has emerged with the advent of information technology and the digital age. It is pathology employing telecommunications technology, as the name implies. In contrast to general pathology, typically performed close to the patient, digital telepathology is generally performed at a distance. Pathology image-rich data is transferred over lengthy ranges for diagnosis, education, and research.
Digital Telepathology Industry (From 2018 to 2022):
| CAGR | 7.5% |
|---|---|
| Market Size - 2018 | US$ 539.76 million |
| Market Size - 2022 | US$ 721.2 million |
Digital Telepathology Industry (From 2023 to 2033):
| CAGR | 9.7% |
|---|---|
| Market Size - 2023 | US$ 776.8 million |
| Market Size - 2033 | US$ 1962.2 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The digital telepathology industry witnessed significant advancements and growth from 2018 to 2022, with the adoption of cutting-edge technologies and increasing demand for remote diagnostics. Also, during this period, integrating artificial intelligence and machine learning algorithms enhanced the accuracy and efficiency of digital pathology solutions, revolutionizing healthcare practices worldwide.
Looking ahead to the booming era of 2023 to 2033, the digital telepathology market is poised for even great expansion, and anticipated factors forcing this growth include:
The global digitalization of healthcare infrastructures is expected to fuel the adoption of digital telepathology systems.
This transformative era is likely to witness remarkable developments in real-time collaboration, virtual consultations, and data analytics for comprehensive pathology insights. As the demand for fast and accurate diagnostic solutions rises, the digital telepathology industry is set to play a pivotal role in shaping the future of diagnostic medicine and improving patient outcomes.
The information technology wave broadening the world may undoubtedly be one of the primary drivers of the digital telepathology business. Western countries already have a strong digital infrastructure, but Internet penetration in the developing world is steadily increasing.
Pathologists can examine, study, and diagnose patients in remote areas of the country and anywhere in the world. A second factor is the flexibility and ease with which a second opinion can be obtained.
The digital telepathology industry may permit pathologists worldwide to consult with their peers in other countries, ensuring an accurate diagnosis. According to the World Health Organization, cancer cases are expected to rise nearly 70% over the next two decades, with almost 1.4 million misdiagnosed. As a result, a prompt (and appropriate) diagnosis may be critical in saving millions of lives.
The third driver is expected to be increased digitization in the research field. Digital pathology is suitable for medical education, histopathology, and even the examination of frozen section specimens. Moreover, pathologists could use digital software to transform physical data into digital files, eliminating the need to store it physically. This would also help them reduce costs and increase efficiency.
Principal Consultant
The digital telepathology industry faces multiple challenges and the most significant of which is cost. The expense of digital telepathology equipment is a barrier in developing countries. Government subsidies are usually unavailable, making the initial investment difficult.
Concerns about regulatory compliance are another issue. As digital telepathology treads a fine line between medicine and technology, each country's laws may differ. There may also be opposition from pathologists. Few pathologists can truly operate these systems today, and many hesitate to trust the results. These are some factors why the digital telepathology market is still limited.
| Category | Application |
|---|---|
| Leading Segment | Clinical Pathology |
| Market Share | 29.1% |
| Category | End User |
|---|---|
| Leading Segment | Hospitals |
| Market Share | 34.1% |
Hospitals dominate the digital telepathology industry in sales due to several important factors. Hospitals are the key end users of diagnostic solutions since they are at the forefront of patient care.
Hospitals are adopting digital telepathology technologies to optimize their processes as several pathology cases rise, moving the demand for quick and precise diagnosis. Without regard to geographic limitations, digital telepathology enables hospitals to benefit from distant pathologists' professional judgment and advice, enhancing diagnostic precision and accelerating the diagnosis process.
Hospitals frequently have high budgets and resources than other end users, enabling them to invest in cutting-edge digital pathology solutions that meet their unique demands and dramatically boost digital telepathology sales.
Clinical pathology commands the digital telepathology market due to its critical role in normal medical diagnosis and patient care. Clinical pathology is a crucial component of pathology and entails the study and analysis of physiological fluids and tissues for diagnosing and treating diseases.
Pathologists may now quickly and effectively analyze and interpret digital slides from a distance because of the widespread use of digital telepathology in clinical settings. Also, this improved accessibility and quick turnaround for crucial results have increased productivity and better patient care. Clinical pathology stands out as a key sales driver in the digital telepathology business due to the increasing importance placed on precise and quick diagnosis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Market CAGR (From 2023 to 2033) |
|---|---|
| Australia | 9.6% |
| China | 17.3% |
| India | 18.8% |
| United Kingdom | 10.4% |
North America is a considerable market, with moderate growth expected over the next decade. North America accounts for a market share of 39.9% of the global digital telepathology business due to the factors such as:
The market is aided by world-class medical education and research facilities, the eager adoption of technology, and the availability of government remuneration in critical fields in North America. Canada has a high growth potential, with a 4.6% CAGR, driven by industrialization and investment opportunities in healthcare facilities.
Europe is accounting for a market share of 23.9% of the global digital telepathology industry. Europe is the second most extensive market, but growth is expected to be flat or negative. Due to the high prevalence of cancer in this region, the digital telepathology business may continue to thrive.
The United Kingdom may account for a significant share of Europe's market revenue by 2033, surpassing Germany due to increased healthcare research spending.
| Countries | Market Share (2023) |
|---|---|
| United States | 35.8% |
| Germany | 4.9% |
| Japan | 6.7% |
Asia Pacific’s digital telepathology market is experiencing significant growth, driven by technological advancements, increasing healthcare infrastructure, and growing demand for remote diagnostic solutions. With countries like China, India, and Japan at the forefront, the region's healthcare industry is adopting digital pathology to enhance patient care and streamline pathology workflows.
The rising prevalence of chronic diseases and a surge in telehealth services further expand the market. In addition, the collaborations between regional and international players foster innovation and drive the adoption of digital telepathology solutions. As the region embraces digital healthcare, Asia Pacific’s digital telepathology market is poised for continued development and success.
Manufacturers are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interests of potential buyers and create a large customer base. For example,
Some of the leading digital telepathology manufacturers in the market include Leica Biosystems, Ventana Medical Systems, Inc., GE Healthcare, Olympus Corporation, Philips Healthcare, MikroSkan Technologies, Inc., and many others.
Key digital telepathology providers are adopting new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc., to increase their sales and gain a competitive edge in the global digital telepathology business.
Prominent Digital Telepathology Manufacturers
Current Developments
| Company | Royal Philips |
|---|---|
| Strategy | Introduced Philips IntelliSite in 2021 |
| Details | Royal Philips, a Dutch health technology company, introduced IntelliSite, its new enterprise-wide digital pathology platform, in October 2021. The product includes scalable software tools to streamline workflows, boost diagnostic confidence, facilitate collaboration, integrate artificial intelligence (AI), and boost pathology lab efficiency. |
| Company | MikroScanTM SL5-E |
|---|---|
| Strategy | Launch of MikroScanTM SL5-E's Two-in-One System |
| Details | MikroScanTM SL5-E was introduced by MikroSkan Technologies in September 2021. The SL5-E is a dual-mode system that combines two distinct capabilities into a single, convenient device. Users choose a digital telepathology scanning mode for creating and interpreting digitalized tissue samples or a traditional pathology scanning mode. |
| Company | Olympus |
|---|---|
| Strategy | Olympus and Grundium Partnered for Accessible Telepathology |
| Details | Olympus and Grundium collaborated in July 2021 to make digital pathology accessible. Collaboration produces an affordable telepathology solution for medical professionals. |
From 2018 to 2022, global sales increased at a CAGR of 7.5%.
The market is expected to continue to evolve at a 9.7% CAGR through 2033.
The digital telepathology market is expected to climb to US$ 1962.2 million by 2033.
The market is expected to be valued at US$ 776.8 million in 2023.
During the anticipated period, hospitals possess a segment share of 34.1%.
North America commands a 39.9% market share of the global market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Medical 5.3.2. Education 5.3.3. Others 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033 6.3.1. Hospitals 6.3.2. School 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA. 8.2.1.2. Canada 8.2.2. By Type 8.2.3. By End Use 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Type 8.3.3. By End Use 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Type 9.2.3. By End Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By End Use 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Type 10.2.3. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By End Use 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Type 11.2.3. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By End Use 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Type 12.2.3. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By End Use 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Type 13.2.3. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By End Use 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Type 14.2.3. By End Use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By End Use 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Type 15.1.2.2. By End Use 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Type 15.2.2.2. By End Use 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Type 15.3.2.2. By End Use 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Type 15.4.2.2. By End Use 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Type 15.5.2.2. By End Use 15.6. UK. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Type 15.6.2.2. By End Use 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Type 15.7.2.2. By End Use 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Type 15.8.2.2. By End Use 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Type 15.9.2.2. By End Use 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Type 15.10.2.2. By End Use 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Type 15.11.2.2. By End Use 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Type 15.12.2.2. By End Use 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Type 15.13.2.2. By End Use 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Type 15.14.2.2. By End Use 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Type 15.15.2.2. By End Use 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Type 15.16.2.2. By End Use 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Type 15.17.2.2. By End Use 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Type 15.18.2.2. By End Use 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Type 15.19.2.2. By End Use 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Type 15.20.2.2. By End Use 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Type 15.21.2.2. By End Use 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Type 15.22.2.2. By End Use 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Type 15.23.2.2. By End Use 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By End Use 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Leica Biosystems 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Ventana Medical Systems Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. GE Healthcare 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Olympus Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Philips Healthcare 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. MikroSkan Technologies Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Kanteron Systems 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Proscia 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Inspirata 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Glencoe Software 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. OptraSCAN 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Digital Telepathology Market
